CC
TMO icon

Capital Counsel’s Thermo Fisher Scientific TMO Stock Holding History

Capital Counsel’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$391K Sell
796
-1
-0.1% -$543 0.02% 45
2025
Q4 		$462K Hold
797
– – 0.02% 42
2025
Q3 		$387K Sell
797
-7
-0.9% -$3.26K 0.01% 46
2025
Q2 		$326K Sell
804
-323
-29% -$135K 0.01% 42
2025
Q1 		$561K Sell
1,127
-50
-4% -$27.1K 0.02% 36
2024
Q4 		$612K Hold
1,177
– – 0.03% 34
2024
Q3 		$728K Hold
1,177
– – 0.03% 33
2024
Q2 		$651K Sell
1,177
-16
-1% -$9.17K 0.03% 35
2024
Q1 		$693K Buy
1,193
+445
+59% +$250K 0.03% 34
2023
Q4 		$397K Sell
748
-55
-7% -$26.6K 0.02% 39
2023
Q3 		$406K Buy
803
+5
+0.6% +$2.66K 0.02% 37
2023
Q2 		$416K Sell
798
-32
-4% -$17.3K 0.02% 37
2023
Q1 		$478K Hold
830
– – 0.03% 36
2022
Q4 		$457K Sell
830
-20
-2% -$10.6K 0.03% 35
2022
Q3 		$431K Sell
850
-15
-2% -$8.39K 0.03% 38
2022
Q2 		$470K Hold
865
– – 0.03% 38
2022
Q1 		$511K Sell
865
-146
-14% -$83.9K 0.02% 41
2021
Q4 		$675K Sell
1,011
-56
-5% -$35K 0.03% 37
2021
Q3 		$610K Hold
1,067
– – 0.03% 38
2021
Q2 		$538K Hold
1,067
– – 0.03% 41
2021
Q1 		$487K Hold
1,067
– – 0.03% 45
2020
Q4 		$497K Hold
1,067
– – 0.03% 43
2020
Q3 		$471K Hold
1,067
– – 0.03% 42
2020
Q2 		$387K Hold
1,067
– – 0.03% 45
2020
Q1 		$303K Hold
1,067
– – 0.02% 48
2019
Q4 		$347K Buy
1,067
+32
+3% +$9.7K 0.02% 50
2019
Q3 		$301K Hold
1,035
– – 0.02% 50
2019
Q2 		$304K Hold
1,035
– – 0.02% 50
2019
Q1 		$283K Hold
1,035
– – 0.02% 52
2018
Q4 		$232K Hold
1,035
– – 0.02% 54
2018
Q3 		$253K Hold
1,035
– – 0.02% 58
2018
Q2 		$214K Buy
+1,035
New +$220K 0.02% 56

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Counsel's TMO Position: Q1 2026 in Review

Capital Counsel reduced its Thermo Fisher Scientific (TMO) stake by 0.13% in Q1 2026, selling an estimated $543 and leaving 796 shares worth $391K. The position accounts for 0.02% of the portfolio, ranked #45.

Capital Counsel first reported a position in TMO in Q2 2018 and has held it in 32 quarters since. The position peaked at $728K in Q3 2024. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Capital Counsel held 796 shares of Thermo Fisher Scientific worth $391K as of Q1 2026.
  • Capital Counsel sold 1 Thermo Fisher Scientific share in Q1 2026, an estimated $543.
  • Thermo Fisher Scientific made up 0.02% of Capital Counsel's portfolio in Q1 2026, its #45 holding.
  • Capital Counsel first reported a position in Thermo Fisher Scientific in Q2 2018 and has held it in 32 quarters since.
  • Capital Counsel's Thermo Fisher Scientific position peaked at $728K in Q3 2024.
  • 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Capital Counsel's 13F filing for Q1 2026, filed 15 May 2026.